- Home
- GITS vs APM Comparison
GITS vs APM Comparison
Compare GITS & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GITS
- APM
- Stock Information
- Founded
- GITS 2018
- APM 2010
- Country
- GITS South Korea
- APM United Kingdom
- Employees
- GITS N/A
- APM N/A
- Industry
- GITS
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- GITS
- APM Health Care
- Exchange
- GITS Nasdaq
- APM Nasdaq
- Market Cap
- GITS 4.8M
- APM 5.6M
- IPO Year
- GITS N/A
- APM 2018
- Fundamental
- Price
- GITS $1.17
- APM $0.99
- Analyst Decision
- GITS
- APM
- Analyst Count
- GITS 0
- APM 0
- Target Price
- GITS N/A
- APM N/A
- AVG Volume (30 Days)
- GITS 86.4K
- APM 138.3K
- Earning Date
- GITS 11-20-2024
- APM 05-06-2025
- Dividend Yield
- GITS N/A
- APM N/A
- EPS Growth
- GITS N/A
- APM N/A
- EPS
- GITS N/A
- APM 0.00
- Revenue
- GITS N/A
- APM N/A
- Revenue This Year
- GITS N/A
- APM $157,729.10
- Revenue Next Year
- GITS N/A
- APM N/A
- P/E Ratio
- GITS N/A
- APM $270.99
- Revenue Growth
- GITS 85.47
- APM N/A
- 52 Week Low
- GITS $0.10
- APM $0.46
- 52 Week High
- GITS $5.06
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- GITS N/A
- APM 51.54
- Support Level
- GITS N/A
- APM $0.79
- Resistance Level
- GITS N/A
- APM $0.97
- Average True Range (ATR)
- GITS 0.00
- APM 0.12
- MACD
- GITS 0.00
- APM 0.02
- Stochastic Oscillator
- GITS 0.00
- APM 33.74
About GITS Global Interactive Technologies Inc. Common Stock
Global Interactive Technologies Inc, formerly Hanryu Holdings Inc is the creator of the engaging social media platform, FANTOO. Through FANTOO, it provides a multi-media platform for its users to interact with other like-minded users, share their appreciation of various types of entertainment and cultures, create their content, enjoy content, and engage in commerce.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.